Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

G1 Therapeutics, Inc. (GTHX)

2.68   0.1 (3.88%) 03-31 16:00
Open: 2.6 Pre. Close: 2.58
High: 2.725 Low: 2.6
Volume: 581,976 Market Cap: 144(M)

Technical analysis

as of: 2023-03-31 4:19:13 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.01     One year: 4.64
Support: Support1: 2.54    Support2: 2.12
Resistance: Resistance1: 3.43    Resistance2: 3.98
Pivot: 2.9
Moving Average: MA(5): 2.68     MA(20): 3.01
MA(100): 5.46     MA(250): 7.53
MACD: MACD(12,26): -0.5     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 13.9     %D(3): 14.3
RSI: RSI(14): 35.8
52-week: High: 17.48  Low: 2.54
Average Vol(K): 3-Month: 1,301 (K)  10-Days: 1,034 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GTHX ] has closed above bottom band by 28.7%. Bollinger Bands are 63.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.8 - 2.81 2.81 - 2.82
Low: 2.52 - 2.54 2.54 - 2.56
Close: 2.56 - 2.58 2.58 - 2.6

Company Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Headline News

Tue, 28 Mar 2023
Genor Biopharma : Announces Acceptance of New Drug Application in China for GB491 (Lerociclib) -

Tue, 21 Mar 2023
G1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Rating of ... - MarketBeat

Mon, 06 Mar 2023
Q1 2023 Earnings Estimate for G1 Therapeutics, Inc. (NASDAQ ... - MarketBeat

Sat, 04 Mar 2023
Tudor Investment Corp Et Al Has $1.05 Million Stock Position in G1 ... - MarketBeat

Fri, 03 Mar 2023
What is the Market's View on G1 Therapeutics Inc (GTHX) Stock's ... - InvestorsObserver

Fri, 03 Mar 2023
G1 Therapeutics: Unexpected Setbacks Yet Value Remains ... - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 52 (M)
Shares Float 45 (M)
% Held by Insiders 7.6 (%)
% Held by Institutions 51.1 (%)
Shares Short 2,860 (K)
Shares Short P.Month 3,120 (K)

Stock Financials

EPS -3.22
EPS Est Next Qtl -0.57
EPS Est This Year -2.93
EPS Est Next Year -2.32
Book Value (p.s.) 1.34
Profit Margin (%) -287.7
Operating Margin (%) -265.5
Return on Assets (ttm) -38.6
Return on Equity (ttm) -139.1
Qtrly Rev. Growth 76.8
Gross Profit (p.s.) 0.92
Sales Per Share 0.99
EBITDA (p.s.) -2.63
Qtrly Earnings Growth 0
Operating Cash Flow -129 (M)
Levered Free Cash Flow -74 (M)

Stock Valuations

PE Ratio -0.84
PEG Ratio 0
Price to Book value 2
Price to Sales 2.69
Price to Cash Flow -1.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.